ArticleRheumatology advances in practice2025
The comparative prevalence of comorbidities across rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis.
Article in Rheumatology advances in practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comorbidity Profiles at Diagnosis in Rheumatoid Arthritis Versus Psoriatic Arthritis: A Nationwide Polish Claims-Based Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Inflammatory arthritis (IA) is associated with a high comorbidity burden, yet few studies have compared comorbidities across IA subtypes. We aimed to compare 39 comorbidities across RA, PsA and axial spondyloarthritis (axSpA). Methods: We used UK Biobank data from over 500 000 participants aged 40-69 years. Baseline data for IA and comorbidities were identified via ICD-10 codes, primary care records and/or self-report. Analysis of variance (ANOVA) and chi-squared tests were used for group comparisons, and logistic regression was used to estimate adjusted odds ratios (ORs) for comorbidities in IA versus controls. Results: Of 230 055 participants (45.4% male; mean age 56.5 years), 1969 had RA, 606 PsA and 797 axSpA. Hypertension (prevalence 9.0-11.1%) and dyspepsia (5.3-7.9%) were more prevalent in IA than in controls. Individuals with RA had significantly higher odds of atherosclerotic cardiovascular diseases, including coronary artery disease (OR 2.1, 95% confidence interval [CI] 1.66, 2.67), stroke/transient ischaemic attack (TIA) (OR 1.78, 95% CI 1.09, 2.89) and peripheral vascular disease (OR 1.90, 95% CI 1.21, 2.99). Those with axSpA had higher odds of heart failure (OR 2.37, 95% CI 1.29, 4.34), atrial fibrillation (OR 1.59, 95% CI 1.03, 2.45) and epilepsy (OR 2.33, 95% CI 1.10, 4.94). Conclusion: IA is linked to increased comorbidity prevalence, notably in cardiovascular, respiratory and gastrointestinal systems. The prevalence and odds of developing atherosclerotic cardiovascular disease were highest in those with RA. Individuals with axSpA have increased odds of developing epilepsy. These findings highlight the diverse comorbidity profiles across IA subtypes and support tailored management approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.